Search
Nektar Therapeutics
NKTRAdd to Watchlist
60.980USD
+0.060+0.10%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
1.80BMarket Cap
LossP/E TTM
Financial Health
Currency: USD Updated: 2026-06-18 The current financial score of Nektar Therapeutics is 6.18, ranking 281 out of 389 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 10.86M, representing a year-over-year increase of 3.83%, while its net profit experienced a year-over-year increase of 11.75%.
Financials
6.50
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.64
Total revenue
Operating profit
Total assets
SG&A
Relevant data have not been disclosed by the company yet.
Operational Efficiency
2.98
Cash flow from operating activities
Income after tax
Relevant data have not been disclosed by the company yet.
Growth Potential
6.65
Cash flow from operating activities
Total revenue
Relevant data have not been disclosed by the company yet.
Shareholder Returns
7.13
Free cash flow
Relevant data have not been disclosed by the company yet.
